{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:26:43Z","timestamp":1790810803979,"version":"4.1.0"},"reference-count":37,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T00:00:00Z","timestamp":1749254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>We assessed the efficacy of the lung immune prognostic index (LIPI) in predicting the progression of pathological T3 renal cell carcinoma (RCC). The LIPI scores of patients with pathological T3 RCC were calculated in the pre- and post-operative phases. Patients were divided into zero-point, one-point, and two-point groups according to their LIPI score and into the upstage and non-upstage groups according to the pre- and post-operative increase in LIPI score. Overall survival (OS) was evaluated using Kaplan\u2013Meier curves stratified by group. Univariate and multivariate analyses of OS were performed via Cox proportional hazard regression analysis. LIPI scores were calculated in 80 patients wherein blood sampling data were available. The upstage and non-upstage groups comprised eight and seventy-two patients, respectively. Kaplan\u2013Meier curves showed a significant difference in the pre- to post-operative LIPI score upstage group. LIPI score change was a poor prognostic factor using univariate analysis (OS: hazard ratio (HR) = 4.10, 95% confidence interval (CI) = 1.07\u201315.61, p = 0.038) and multivariate analysis (OS: HR = 4.38, 95% CI = 1.13\u201316.89, p = 0.031). An increase in the LIPI score in the pre-operative phase was a poor prognostic factor for pathological T3 RCC.<\/jats:p>","DOI":"10.3390\/curroncol32060335","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T05:54:05Z","timestamp":1749448445000},"page":"335","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Increased Pre-Operative Lung Immune Prognostic Index Score Is a Prognostic Factor in Cases of Pathological T3 Renal Cell Carcinoma"],"prefix":"10.3390","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5067-0241","authenticated-orcid":false,"given":"Hayato","family":"Hoshina","sequence":"first","affiliation":[{"name":"Department of Urology, Jichi Medical University Hospital, Shimotsuke 329-0498, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0901-3209","authenticated-orcid":false,"given":"Toru","family":"Sugihara","sequence":"additional","affiliation":[{"name":"Department of Urology, Jichi Medical University Hospital, Shimotsuke 329-0498, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Kurokawa","sequence":"additional","affiliation":[{"name":"Department of Urology, Jichi Medical University Hospital, Shimotsuke 329-0498, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ei-ichiro","family":"Takaoka","sequence":"additional","affiliation":[{"name":"Department of Urology, Jichi Medical University Hospital, Shimotsuke 329-0498, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Urology, Jichi Medical University Hospital, Shimotsuke 329-0498, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruki","family":"Kume","sequence":"additional","affiliation":[{"name":"Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8657, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Fujimura","sequence":"additional","affiliation":[{"name":"Department of Urology, Jichi Medical University Hospital, Shimotsuke 329-0498, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/COC.0000000000001035","article-title":"Correlation of Lung Immune Prognostic Index with Efficacy of PD-1\/PD-L1 Inhibitor Combined with Chemotherapy and Prognosis in Patients with Advanced Non-Small Cell Lung Cancer","volume":"46","author":"Zhu","year":"2023","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"108039","DOI":"10.1016\/j.lungcan.2024.108039","article-title":"Validation of the Lung Immune Prognostic Index in patients with untreated advanced non-small cell lung cancer: Post hoc analysis of the IMpower 130, 131 and 150 trials","volume":"199","author":"Auclin","year":"2025","journal-title":"Lung Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Liao, S., Sun, S., Lu, H., Wu, J., Wu, J., Wu, Z., Xi, J., Liao, W., and Wang, Y. (2025). Neutrophil-to-lymphocyte ratio-based prognostic score can predict outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy plus chemotherapy. BMC Cancer, 25.","DOI":"10.1186\/s12885-025-13811-y"},{"key":"ref_5","first-page":"1484","article-title":"Lung immune prognostic index (LIPI) as a prognostic factor in patients with extensive-stage small cell lung cancer treated with first-line chemoimmunotherapy","volume":"27","year":"2025","journal-title":"Clin. Transl. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Meyers, D.E., Stukalin, I., Vallerand, I.A., Lewinson, R.T., Suo, A., Dean, M., North, S., Pabani, A., Cheng, T., and Heng, D.Y.C. (2019). The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors. Cancers, 11.","DOI":"10.3390\/cancers11111713"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Pierro, M., Baldini, C., Auclin, E., Vincent, H., Varga, A., Martin Romano, P., Vuagnat, P., Besse, B., Planchard, D., and Hollebecque, A. (2022). Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score. Cancers, 14.","DOI":"10.3390\/cancers14205078"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s40001-023-01198-0","article-title":"Association of the pretreatment lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced hepatocellular carcinoma","volume":"28","author":"Sun","year":"2023","journal-title":"Eur. J. Med. Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1200\/JCO.2022.40.6_suppl.320","article-title":"Efficacy of first-line combination therapy in metastatic renal cell carcinoma (mRCC) patients (pts) with poor performance status (PS)","volume":"40","author":"Carril","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall survival with adjuvant pembrolizumab in renal-cell carcinoma","volume":"390","author":"Choueiri","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(22)00487-9","article-title":"Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Powles","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1007\/s11864-023-01161-5","article-title":"Treatment Landscape of Renal Cell Carcinoma","volume":"24","author":"Chen","year":"2023","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1200\/JCO.2022.40.6_suppl.290","article-title":"Pembrolizumab as post nephrectomy adjuvant therapy for patients with renal cell carcinoma: Results from 30-month follow-up of KEYNOTE-564","volume":"40","author":"Choueiri","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3894","DOI":"10.1245\/s10434-024-15121-2","article-title":"Efficacy Assessment of Post-nephrectomy Adjuvant Therapies in Patients with Renal Cell Carcinoma","volume":"31","author":"Ding","year":"2024","journal-title":"Ann. Surg. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e723","DOI":"10.1016\/j.clgc.2020.05.002","article-title":"Oncologic and Functional Outcomes of Radical and Partial Nephrectomy in pT3a Pathologically Upstaged Renal Cell Carcinoma: A Multi-institutional Analysis","volume":"18","author":"Patel","year":"2020","journal-title":"Clin. Genitourin. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/annonc\/mdw016","article-title":"Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: Prognostic relevance in metastatic melanoma patients receiving ipilimumab","volume":"27","author":"Ferrucci","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"He, X., Wang, Y., Ye, Q., Wang, Y., Min, L., Luo, Y., Zhou, Y., and Tu, C. (2022). Lung immune prognostic index could predict metastasis in patients with osteosarcoma. Front. Surg., 9.","DOI":"10.3389\/fsurg.2022.923427"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"114048","DOI":"10.1016\/j.ejca.2024.114048","article-title":"Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma","volume":"204","author":"Lavaud","year":"2024","journal-title":"Eur. J. Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s10147-021-02059-8","article-title":"The prognostic value of the preoperative lung immune prognostic index in patients with urothelial bladder cancer undergoing radical cystectomy","volume":"27","author":"Obayashi","year":"2022","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e001079","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: Extended 4-year follow-up of the phase III CheckMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1200\/JCO.2022.40.16_suppl.4538","article-title":"Prognostic value of the lung immune prognostic index in patients with untreated advanced renal cell carcinoma (aRCC) receiving nivolumab plus ipilimumab (N+I) or sunitinib (SUN) in the CheckMate 214 trial","volume":"40","author":"Motzer","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.2023.41.6_suppl.719","article-title":"The Lung Immune Prognostic Index (LIPI) stratifies prognostic groups and correlates with gut microbiota (GM) in patients with advanced renal cell carcinoma (RCC)","volume":"41","author":"Silva","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.suronc.2013.12.001","article-title":"A systematic review and meta-analysis on the impact of pre-operative neutrophil lymphocyte ratio on long term outcomes after curative intent resection of solid tumours","volume":"23","author":"Paramanathan","year":"2014","journal-title":"Surg. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Gu, X.B., Tian, T., Tian, X.J., and Zhang, X.J. (2015). Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: A meta-analysis. Sci. Rep., 5.","DOI":"10.1038\/srep12493"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.3892\/ol.2016.4381","article-title":"Derived neutrophil\/lymphocyte ratio predicts gemcitabine therapy outcome in unresectable pancreatic cancer","volume":"11","author":"Suzuki","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.urolonc.2013.09.008","article-title":"Clinical prognostic factors associated with outcome in patients with renal cell cancer with prior tyrosine kinase inhibitors or immunotherapy treated with everolimus","volume":"32","author":"Amato","year":"2014","journal-title":"Urol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3233\/BLC-160055","article-title":"Elevated derived neutrophil-to-lymphocyte ratio corresponds with poor outcome in patients undergoing pre-operative chemotherapy in muscle-invasive bladder cancer","volume":"2","author":"Zwarthoff","year":"2016","journal-title":"Bladder Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ishiyama, Y., Kondo, T., Yoshida, K., Iizuka, J., and Takagi, T. (2024). Prognostic value of the lung immune prognostic index on recurrence after radical surgery for high-risk renal cell carcinoma. Cancers, 16.","DOI":"10.3390\/cancers16040776"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.euf.2020.05.013","article-title":"Upstaging to pT3a in patients undergoing partial or radical nephrectomy for cT1 renal tumors: A systematic review and meta-analysis of outcomes and predictive factors","volume":"7","author":"Veccia","year":"2021","journal-title":"Eur. Urol. Focus."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.urology.2019.11.036","article-title":"Risk factors for upstaging, recurrence, and mortality in clinical T1-2 renal cell carcinoma patients upstage to pT3a disease: An international analysis utilizing the 8th edition of the tumor-node-metastasis staging criteria","volume":"138","author":"Hamilton","year":"2020","journal-title":"Urology"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.urology.2018.04.002","article-title":"Multi-institutional survival analysis of incidental pathologic T3a upstaging in clinical T1 renal cell carcinoma following partial nephrectomy","volume":"117","author":"Russell","year":"2018","journal-title":"Urology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1464-410X.2006.06497.x","article-title":"Increased preoperative serum C-reactive protein level predicts a poor prognosis in patients with localized renal cell carcinoma","volume":"99","author":"Komai","year":"2007","journal-title":"BJU Int."},{"key":"ref_34","first-page":"E348","article-title":"Validation of serum C-reactive protein (CRP) as an independent prognostic factor for disease-free survival in patients with localised renal cell carcinoma (RCC)","volume":"111","author":"Klatte","year":"2013","journal-title":"BJU Int."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1007\/s10147-022-02136-6","article-title":"C-reactive protein kinetics to predict recurrence of high-risk renal cell carcinoma after radical surgery","volume":"27","author":"Ishiyama","year":"2022","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.eururo.2015.01.002","article-title":"Impact of rhabdoid differentiation on prognosis for patients with Grade 4 renal cell carcinoma","volume":"68","author":"Zhang","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_37","first-page":"1139","article-title":"Verification of the International Society of Urological Pathology recommendations in Japanese patients with clear cell renal cell carcinoma","volume":"52","author":"Kim","year":"2018","journal-title":"Int. J. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/6\/335\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:48:05Z","timestamp":1760032085000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/32\/6\/335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,7]]},"references-count":37,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,6]]}},"alternative-id":["curroncol32060335"],"URL":"https:\/\/doi.org\/10.3390\/curroncol32060335","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,7]]}}}